Chimeric antigen receptor (CAR) T-cell therapy is a new and rapidly evolving immunotherapy emerging as a novel treatment option for relapsed or refractory lymphomas.
Chimeric antigen receptor (CAR) T-cell therapy is an immune-based therapy used in cancer treatment that has demonstrated efficacy in the management of many hematologic malignancies, suggesting significant impact on oncology practice.
You recently participated in education on Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas. Here is your chance to earn additional CME/CE and test your knowledge. Try your skills at this challenging case.
Patients with relapsed or refractory hematologic disorders like acute lymphoblastic leukemia and diffuse large B-cell lymphoma have poor outcomes and require novel effective therapies.
You recently participated in education on Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas. Here is your chance to earn additional CME/CE and test your knowledge. Try your skills at this challenging case.
The goal of this program is to ensure that members of the interprofessional oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting
This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.
Facebook
X
LinkedIn
Forward